Charles River Laboratories stock fell 1.87 percent after Investor Day

Published on 10/07/2026 at 07:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Charles River Laboratories stock fell to USD 304.96 on October 6, 2026, after a sharp session decline. Q2 EPS beat consensus, while 2026 guidance stayed intact.

CRL, US1598641074, Illustration mit AI erstellt.

Charles River Laboratories stock (ISIN US1598641074) was last at USD 304.96 on the NYSE on October 6, 2026, down 1.87 percent from the prior close. The company also announced a partnership with Autolomous on October 6, according to StockTitan.

Investor Day targets set the frame

At its September 24, 2026 Investor Day, Charles River reaffirmed 2026 organic revenue growth guidance at the upper end of the 0 percent-1 percent range. The company also kept non-GAAP operating margin guidance at 21.0 percent-21.3 percent and non-GAAP EPS guidance at the upper end of USD 11.15-11.45, according to StockTitan.

The longer-term plan targets 5 percent-7 percent organic revenue growth from 2027 through 2030 and a non-GAAP operating margin of 24 percent by 2030. The Create the Future program is expected to generate more than USD 300 million in cumulative savings from 2027 through 2030, although the filing describes those figures as targets rather than financial guidance.

Quarterly earnings beat estimates

Charles River reported adjusted EPS of USD 3.02 for the quarter ended August 5, 2026, compared with consensus of USD 2.77, a USD 0.25 beat, according to MarketBeat. Revenue reached USD 1.0 billion, compared with consensus of USD 980.53 million.

The comparison is mixed: quarterly revenue declined 2.7 percent from the prior year, while the prior-year EPS figure was USD 3.12. That combination makes the upper end of the 2026 EPS range more important than the revenue headline for the current valuation.

Consensus target trails the stock

MarketBeat reported a consensus Moderate Buy rating based on 17 analysts, with an average price target of USD 300.11. The breakdown included one Strong Buy, 13 Buy, two Hold and one Sell rating, according to MarketBeat.

That average target sits below the USD 304.96 last price, while the stock remains USD 28.34 below its 52-week high of USD 333.30. The valuation debate therefore centers on execution against the savings plan, demand recovery and the company's ability to convert bookings into revenue growth.

Charles River Laboratories stock stays near its yearly high

Charles River Laboratories stock was last at USD 304.96 on the NYSE on October 6, 2026, with a session range of USD 300.52-332.83 and volume of 1,923,125 shares. Its market capitalization was USD 14.7 billion on the same date.